| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
47,361,000 |
| Market
Cap: |
722.26(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$15.25 - $15.25 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Aerie Pharmaceuticals is a pharmaceutical company focused on the discovery, development and commercialization of ophthalmic therapies for the treatment of patients with eye diseases and conditions including open-angle glaucoma, dry eye, and diabetic macular edema. Rhopressa® is a once-daily eye drop designed to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Rocklatan® is a once-daily fixed-dose combination of Rhopressa® and latanoprost, a prescribed drug for the treatment of patients with open-angle glaucoma or ocular hypertension. Co. is developing AR-15512, an ophthalmic solution for the treatment of patients with dry eye disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Du Toit Michael |
Director |
– • – |
2017-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
1,150 |
2,850 |
|
- |
|
| Goldberg Murray A |
Director |
– • – |
2017-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
1,150 |
4,550 |
|
- |
|
| Tananbaum James B. |
10% Owner |
– – • |
2017-05-26 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
3,643,191 |
|
- |
|
| Tananbaum James B. |
10% Owner |
– – • |
2017-05-26 |
4 |
S |
$55.95 |
$1,119,000 |
I/I |
(20,000) |
1,950,477 |
|
- |
|
| Cagle Gerald D. |
Director |
– • – |
2017-05-09 |
4 |
B |
$39.90 |
$39,900 |
D/D |
1,000 |
12,900 |
2.39 |
- |
|
| Cagle Gerald D. |
Director |
– • – |
2017-04-19 |
4 |
B |
$41.60 |
$83,400 |
D/D |
2,000 |
11,900 |
2.39 |
- |
|
| Rubino Richard J |
Chief Financial Officer |
• – – |
2017-02-25 |
4 |
D |
$44.55 |
$37,645 |
D/D |
(845) |
402,135 |
|
- |
|
| Kopczynski Casey C. |
Chief Scientific Officer |
• – – |
2017-02-25 |
4 |
D |
$44.55 |
$26,418 |
D/D |
(593) |
185,061 |
|
- |
|
| Anido Vicente Jr |
Chief Executive Officer |
• • – |
2017-02-25 |
4 |
D |
$44.55 |
$67,627 |
D/D |
(1,518) |
87,065 |
|
- |
|
| Mitro Thomas A |
President and COO |
• – – |
2017-02-25 |
4 |
D |
$44.55 |
$49,718 |
D/D |
(1,116) |
34,042 |
|
- |
|
| Rubino Richard J |
Chief Financial Officer |
• – – |
2017-02-24 |
4 |
D |
$44.55 |
$41,521 |
D/D |
(932) |
402,980 |
|
- |
|
| Kopczynski Casey C. |
Chief Scientific Officer |
• – – |
2017-02-24 |
4 |
D |
$44.55 |
$33,012 |
D/D |
(741) |
185,654 |
|
- |
|
| Anido Vicente Jr |
Chief Executive Officer |
• • – |
2017-02-24 |
4 |
D |
$44.55 |
$76,448 |
D/D |
(1,716) |
88,583 |
|
- |
|
| Mitro Thomas A |
President and COO |
• – – |
2017-02-24 |
4 |
D |
$44.55 |
$49,718 |
D/D |
(1,116) |
35,158 |
|
- |
|
| Rubino Richard J |
Chief Financial Officer |
• – – |
2017-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
4,780 |
403,912 |
|
- |
|
| Kopczynski Casey C. |
Chief Scientific Officer |
• – – |
2017-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
4,412 |
186,395 |
|
- |
|
| Anido Vicente Jr |
Chief Executive Officer |
• • – |
2017-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
17,281 |
90,299 |
|
- |
|
| Mitro Thomas A |
President and COO |
• – – |
2017-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
8,824 |
36,274 |
|
- |
|
| Duyk Geoffrey M |
Director |
– • – |
2017-02-15 |
4 |
S |
$46.81 |
$973,438 |
D/D |
(20,796) |
3,400 |
|
- |
|
| Duyk Geoffrey M |
Director |
– • – |
2017-02-14 |
4 |
S |
$46.46 |
$966,059 |
D/D |
(20,795) |
24,196 |
|
- |
|
| Duyk Geoffrey M |
Director |
– • – |
2017-02-14 |
4 |
D |
$46.95 |
$778,243 |
D/D |
(16,576) |
44,991 |
|
- |
|
| Duyk Geoffrey M |
Director |
– • – |
2017-02-14 |
4 |
OE |
$3.15 |
$778,132 |
D/D |
58,167 |
46,870 |
|
- |
|
| Tananbaum James B. |
10% Owner |
– – • |
2016-10-06 |
4 |
S |
$40.34 |
$2,016,995 |
I/I |
(50,000) |
1,672,697 |
|
- |
|
| Tananbaum James B. |
10% Owner |
– – • |
2016-07-22 |
3/A |
IO |
$0.00 |
$0 |
I/I |
0 |
3,370,598 |
|
- |
|
| Tananbaum James B. |
10% Owner |
– – • |
2016-07-22 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
3,120,598 |
|
- |
|
333 Records found
|
|
Page 11 of 14 |
|
|
